Lexaria Bioscience Past Earnings Performance
Past criteria checks 0/6
Lexaria Bioscience's earnings have been declining at an average annual rate of -9.8%, while the Pharmaceuticals industry saw earnings declining at 0.8% annually. Revenues have been growing at an average rate of 0.4% per year.
Key information
-9.8%
Earnings growth rate
15.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 0.4% |
| Return on equity | -89.0% |
| Net Margin | -1,344.0% |
| Last Earnings Update | 29 Feb 2024 |
Recent past performance updates
Recent updates
Lexaria Bioscience gets third patent granted in Japan
Jul 14Lexaria Bioscience's DehydraTECH licensee Cannadips expands internationally
Jul 07Is Lexaria Bioscience (NASDAQ:LEXX) In A Good Position To Deliver On Growth Plans?
Apr 15
We Think Lexaria Bioscience (NASDAQ:LEXX) Can Afford To Drive Business Growth
Dec 07Lexaria Hits New 52-Week High With Positive Data On Enhanced Treatment For COVID-19
Jul 22Revenue & Expenses BreakdownBeta
How Lexaria Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 29 Feb 24 | 0 | -5 | 3 | 3 |
| 30 Nov 23 | 0 | -6 | 3 | 3 |
| 31 Aug 23 | 0 | -7 | 3 | 4 |
| 31 May 23 | 0 | -7 | 3 | 4 |
| 28 Feb 23 | 0 | -7 | 4 | 3 |
| 30 Nov 22 | 0 | -7 | 4 | 2 |
| 31 Aug 22 | 0 | -7 | 5 | 2 |
| 31 May 22 | 0 | -7 | 5 | 2 |
| 28 Feb 22 | 0 | -7 | 6 | 2 |
| 30 Nov 21 | 0 | -7 | 6 | 2 |
| 31 Aug 21 | 1 | -6 | 5 | 1 |
| 31 May 21 | 1 | -5 | 5 | 1 |
| 28 Feb 21 | 1 | -4 | 4 | 0 |
| 30 Nov 20 | 1 | -4 | 4 | 0 |
| 31 Aug 20 | 0 | -4 | 4 | 0 |
| 31 May 20 | 0 | -4 | 4 | 0 |
| 29 Feb 20 | 0 | -4 | 3 | 1 |
| 30 Nov 19 | 0 | -4 | 4 | 1 |
| 31 Aug 19 | 0 | -4 | 4 | 1 |
| 31 May 19 | 0 | -4 | 4 | 1 |
| 28 Feb 19 | 0 | -6 | 6 | 0 |
| 30 Nov 18 | 0 | -7 | 7 | 0 |
| 31 Aug 18 | 0 | -7 | 7 | 0 |
| 31 May 18 | 0 | -6 | 6 | 0 |
| 28 Feb 18 | 0 | -3 | 3 | 0 |
| 30 Nov 17 | 0 | -2 | 2 | 0 |
| 31 Aug 17 | 0 | -2 | 2 | 0 |
| 31 May 17 | 0 | -1 | 1 | 0 |
| 28 Feb 17 | 0 | -1 | 1 | 0 |
| 30 Nov 16 | 0 | -1 | 1 | 0 |
| 31 Aug 16 | 0 | -1 | 1 | 0 |
| 31 May 16 | 0 | -1 | 1 | 0 |
| 29 Feb 16 | 0 | -2 | 2 | 0 |
| 30 Nov 15 | 0 | -2 | 2 | 0 |
| 31 Aug 15 | 0 | -2 | 2 | 0 |
| 31 May 15 | 0 | -2 | 2 | 0 |
| 28 Feb 15 | 0 | -2 | 2 | 0 |
| 30 Nov 14 | 0 | -2 | 2 | 0 |
| 31 Aug 14 | 0 | -2 | 2 | 0 |
| 31 Jul 14 | 1 | -1 | 1 | 0 |
| 30 Apr 14 | 1 | -1 | 1 | 0 |
| 31 Jan 14 | 1 | 0 | 0 | 0 |
| 31 Oct 13 | 0 | -1 | 0 | 0 |
| 31 Jul 13 | 1 | 0 | 0 | 0 |
Quality Earnings: LEXX is currently unprofitable.
Growing Profit Margin: LEXX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LEXX is unprofitable, and losses have increased over the past 5 years at a rate of 9.8% per year.
Accelerating Growth: Unable to compare LEXX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LEXX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.7%).
Return on Equity
High ROE: LEXX has a negative Return on Equity (-88.98%), as it is currently unprofitable.